Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Medline ® Abstracts for References 45,46

of 'Treatment of community-acquired pneumonia in adults who require hospitalization'

Does empirical therapy with a fluoroquinolone or the combination of aβ-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
Ruhe J, Mildvan D
Infect Dis Clin North Am. 2013 Mar;27(1):115-32. Epub 2012 Dec 1.
Community-acquired pneumonia (CAP) is a frequent cause of morbidity and mortality in the United States and worldwide, in particular among older patients and those with significant comorbid conditions. Current guidelines recommend therapy with a fluoroquinolone or aβ-lactam plus a macrolide for the treatment of hospitalized adults with CAP who do not require admission to an intensive care unit. This article provides a brief summary and overview of the existing literature on this topic categorized by the main results; the potential implications for future clinical practice and research are discussed.
Division of Infectious Diseases, Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY 10003, USA. jruhe@chpnet.org
http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed September 2, 2010).
no abstract available